Leading the way to cures

Cure One Cure Many Award

The American Brain Foundation’s Cure One, Cure Many Award program supports breakthrough research in brain disease. The program provides large-scale, catalyst funding to the world’s top researchers who are pursuing the most innovative, cross-cutting approaches to finding diagnoses, treatments, and cures for brain disease. The program targets research topics that cut across multiple disease areas.

Improving Diagnosis for Lewy Body Dementia

In partnership with the Alzheimer’s Association, The Michael J. Fox Foundation for Parkinson’s Research, and the American Academy of Neurology, the American Brain Foundation is seeking to accelerate progress in the diagnosis of Lewy body dementia (LBD). LBD is the most common form of dementia after Alzheimer’s disease.

Currently, LBD can only be definitively diagnosed with a brain autopsy after death. As a result of a delay in diagnosis and misdiagnosis, people with LBD and their caregivers endure daily challenges and uncertainty. The goal of the 2022 Cure One, Cure Many Award is to attract the best minds in brain disease research to find a biomarker (diagnostic test) for LBD.


Proposals for the award will be reviewed by a panel of preeminent scientists, and can address disorders across the LBD spectrum. Projects should specifically have the potential to identify one or more biomarkers that can be used to diagnose Lewy body dementia as the underlying cause of cognitive impairment. Applications for the 2022 Cure One, Cure Many Award will open on July 1, 2021. Grant winners will be selected and announced in late 2021.